Virios therapeutics, inc. reaches alignment with fda on requirements for advancing development candidate imc-2 as treatment for long-covid

Atlanta, jan. 02, 2024 (globe newswire) -- virios therapeutics, inc.  (nasdaq: viri) (the “company”), a development-stage biotechnology company focused on developing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“fm”) and long-covid (“lc”), today announced receipt of the food and drug administration's (“fda”) feedback on requirements for advancing imc-2 (combination of valacyclovir + celecoxib) as a treatment for the fatigue, orthostatic intolerance and other symptoms associated with lc illness, also known as post-acute sequelae of sars-cov-2 infection (“pasc”).
VIRI Ratings Summary
VIRI Quant Ranking